Solvay, Novasep in pharma manufacturing alliance
14 Dec 2006
Five-year agreement includes exclusive synthesis of active ingredients for Solvay
Pompey, France -- Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliance, which includes the exclusive synthesis of two active pharmaceutical ingredients for Solvay, the companies announced 11 Dec.
The companies recently started a strategic manufacturing alliance making Novasep a preferred partner for the development, scale-up and industrial supply of existing and new chemicals and active pharma ingredients. Under the latest deal, Novasep will carry out the large-scale production of Pinaverium bromide and Betahistine in its Mourenx facility.
Novasep and Solvay said they also plan to extend this agreement in the short- to medium-term. This outsourcing is in line with Solvay’s strategy of “shifting selected manufacturing activities to high quality, competitively-priced alternatives,” the Brussels-based major stated.
Novasep of Pompey, France, offers synthesis services based on specialised technologies such as chiral technologies and hazardous chemistry to produce molecules for the pharma industry.